Cloud Infrastructure Showdown: Alphabet vs. CoreWeave
Money

Cloud Infrastructure Showdown: Alphabet vs. CoreWeave

authorBy Bola Sokunbi
DateJun 25, 2026
Read Time2 min

The cloud computing sector is a dynamic arena featuring both established titans and agile newcomers. Giants like Alphabet (NASDAQ: GOOGL) offer extensive cloud services alongside specialized AI computing divisions, while companies such as CoreWeave (NASDAQ: CRWV) are intensely focused on AI infrastructure. This article explores which of these two distinct entities presents a more attractive investment opportunity within this burgeoning technological space.

CoreWeave's strategy is entirely centered on AI cloud computing, necessitating significant expansion of its data center footprint and a path to profitability, both of which are challenging endeavors. A substantial portion of CoreWeave's revenue currently relies on just two major clients, Microsoft and Meta Platforms, highlighting a concentration risk should these key contracts be terminated. In contrast, Alphabet represents a more conservative investment choice due to its highly diversified business model. Cloud computing, while a critical and expanding segment, constitutes only a fraction of its total revenue, bolstered by other profitable ventures like Google Search and YouTube, which provide robust cash flow for infrastructure development. Alphabet's cloud division also benefits from a broad customer base, reducing dependence on any single client, thus offering greater stability for investors.

While CoreWeave demonstrates impressive growth, outpacing Alphabet's Google Cloud segment with a 112% year-over-year revenue increase in Q1 compared to Google Cloud's 63%, its smaller scale means it still generates less overall revenue. Both companies have significant growth prospects, with substantial backlogs indicating future expansion. When evaluating valuations, CoreWeave trades at a price-to-sales ratio under 9, which is considered reasonable for its industry, despite its current unprofitability. Alphabet, being profitable, is typically assessed by its price-to-earnings ratio, which currently stands at nearly 27, suggesting it is priced higher than its recent historical averages but remains competitive among its big tech peers. Given these factors, assessing a clear winner in terms of valuation is complex, leading to a nuanced conclusion.

Ultimately, the preferred investment hinges on individual investment philosophy. For those seeking steady, secure growth with moderate upside, Alphabet is likely the more suitable option. Conversely, investors willing to embrace higher risk for potentially greater returns might find CoreWeave more appealing. Both companies hold the promise of substantial gains in the AI investment landscape, reflecting the innovative spirit and opportunities within the technology sector. Investing in such companies contributes to advancing technological frontiers, driving economic progress, and fostering a future of continued innovation and development.

More Articles
Money
Leading Investors Divest, Yet Stocks Continue to Rise: An Analysis
Despite prominent investors like Stanley Druckenmiller, David Tepper, and Carl Icahn selling off significant stakes in Alphabet, Delta Air Lines, and Southwest Gas in Q1 2026, these stocks have continued their upward trajectory. This article explores the discrepancy between these high-profile exits and the persistent bullish sentiment from Wall Street analysts, examining the underlying data and fundamental strengths of each company to determine if retail investors should reconsider their positions.
By Ramit SethiJun 25, 2026
Money
Mirum Pharmaceuticals: A Potential Growth Story in Rare Diseases?
Mirum Pharmaceuticals is gaining attention as a promising entity in the rare disease sector, particularly following new data on its FOP treatment, zilurgisertib. Despite a Phase 2b study not meeting its primary endpoint, updated findings show encouraging clinical activity, prompting Citizens to raise its price target for MIRM. The company also recently granted inducement awards to new hires, aligning with its growth trajectory in developing therapies for liver and metabolic disorders caused by bile acid dysfunction.
By Bola SokunbiJun 25, 2026
Money
Upstream Bio: A Promising Biotech for Inflammatory Diseases
Upstream Bio, Inc. (NASDAQ: UPB) is gaining recognition as a potential opportunity in the biotech sector. Analyst Matthew Caufield initiated coverage with a 'Buy' rating and a $36 price target, highlighting the company's lead candidate, verekitug, an antibody targeting the thymic stromal lymphopoietin receptor. Recent Phase 2 trial results for verekitug in chronic rhinosinusitis with nasal polyps further support its potential, showing significant improvement and addressing an unmet medical need.
By Scott PapeJun 25, 2026
Money
Bed Bath & Beyond's Strategic Initiatives: Coupon Hunt and Home Services Expansion
Bed Bath & Beyond is actively working to rebuild customer engagement and expand its service offerings. The company recently launched a 'Legendary Coupon Hunt' to reconnect with long-time customers, offering a significant home transformation prize. Additionally, BBBY acquired Installed Right and SFV Services to bolster its home services platform, adding installation, renovation, and project management capabilities, which is expected to boost revenue and adjusted EBITDA.
By Dave RamseyJun 25, 2026
Money
Edgewise Therapeutics Sees Price Target Boosted to $59 Following Positive HCM Trial Outcomes
Edgewise Therapeutics (EWTX) had its price target raised to $59 by RBC Capital, which maintained an Outperform rating. This increase comes after favorable 12-week results from the '7500 HCM trial, demonstrating promising safety and effectiveness. RBC Capital anticipates these findings could pave the way for a Phase 3 trial without requiring titration echocardiograms, enhancing real-world applicability. The firm also highlighted EWTX's broader cardiology potential, foreseeing substantial long-term expansion from its '7500 program and overall pipeline. The company recently divested its muscular dystrophy business for $2.65 billion, allowing it to concentrate on its cardiovascular portfolio.
By Mr. Money MustacheJun 25, 2026